Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected ...

Sanofi’s third-quarter results showed the company’s pharma and vaccines businesses grew faster and were more profitable than its consumer-health unit Opella.

While the inquiry gets most things right, as vaccine experts, we argue the government response should be broadened in three ...

Sanofi announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.

Investing.com -- Sanofi (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, buoyed by strong vaccine revenues and robust early sales ...

Vaccines sales rose a currency-adjusted 25.5% to 3.8 billion euros in the quarter, ahead of a 3.2 billion euro analyst consensus. Sanofi is nearing a sale of a 50% stake in its consumer unit ...

Sanofi expects a low single-digit decline in flu shot sales due to the soft vaccination rate. 2024 vaccine sales are expected to grow high single-digit compared to the earlier mid-single-digit range.